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RÉSUMÉ 
Les g lioblastomes multifo rmes (G BM), cons idérés parmi les cancers les plus 
agress ifs du cerveau, représentent entre 1-2% de l'ensemble des tumeurs adul tes. Q uoique 
plutôt rares, ceux-ci sont part iculièrement diffi ciles à tra iter, d 'où le sombre pronostic 
re li é à la malad ie. De plus, les causes de la pathologie sont encore peu connues. Un 
obstacle cons idérable dans le traitement des G BM, et dans les malad ies du système 
nerve ux central (SNC) en généra l, est le passage de la barrière hémato-encépha li que 
(BH E) par les substances pharmaco logiques . Ang iopep-2, un court peptide inerte, a été 
déve loppé comme système de vectori sati on de médicaments au cerveau. Cette mo lécul e 
est interna li sée sé lectivement à travers la BHE par un mécani sme dépendant de la 
proté ine Low-Density Lipoprotein Receptor-Related Protein-1 (LRP-1 ). La conjuga ison 
de molécules thérapeutiq ues à Angiopep-2 a permis le déve lo ppement de méd icaments 
c iblant le cerveau. LRP-1 est un large récepteur membranaire présent à la swface des 
ce llules endothé lia les de la BH E, en plus d ' être expri mé dans les cellul es cancéreuses du 
cerveau. LRP- 1 possède de nombreuses fo nctions, dont l'inte rnali sation de ligands 
extracellu laires. Il est également associé à la survie et à la mig rati on ce llula ire. De plus, 
LRP-1 est impliqué dans la déterm ination du grade et du phénotype du cancer du cerveau. 
Il a été démontré que l' express ion et la fo nction de LRP-1 étaient régu lées par la proté ine 
Membrane Type-1 Mal!-ix Metalloproteinase (MT I-MMP). MT I-MM P est capab le de 
c li ver LRP-1 , et joue conséquemment un rô le dans la régulat ion des fo nctions qui 
dépendent de LRP- 1. Dans notre recherche, nous avons décidé d'explorer la régulation de 
l'expression de LRP- 1, par MT I-MMP, dans une lignée de ce llules de g liome. No us 
avons tra ité le modèle ce ll ulai re U87-GM avec de la Concanavaline A (ConA), connue 
pour sa capacité à induire l'activation et la transcription de MT I-MMP. Nos résultats ont 
démontré une rapide internali sation a insi qu une dégradation de LRP-1. Cependant, par 
répress ion génique de MT I-MMP et de d 'autres médiateurs impli qués dans la vo ie de 
signa lisati on de la ConA, a insi que par l' utili sation d ' inhibiteurs sé lect ifs, nous avons 
établi que cet effet n'éta it pas médié par MT I-MMP, ni par une interaction directe entre 
la ConA et la cellule . Sachant que les effets de la ConA impl iquent des perturbat ions du 
cytosquele tte d'actine, nous avons inh ibé la po lyméri sation de l'actine et des mi crotubul es 
et découvert que les effets sur LRP- 1 éta ient dus à la perturbati on de l'actine. De plus, ce 
processus d ' internalisation et de dégradati on de LRP- 1 a mené à une réd ucti on 
significat ive de la capac ité des ce llules U87 à interna li ser l' Angiopep-2 et l' a lpha-2 
macrog lobuline, deux ligands de LRP-1. No us conc luons donc que l'intégrité du 
cytosq ue lette d'actine est requi se pour les foncti ons de LRP- 1 à la surface de la cellule. 
No données démo ntrent éga lement la nécessité de retrouver LRP-1 à la s urface ce llula ire 
dans la vectorisati on de molécules thérapeutiques, couplées à 1 'Ang iopep-2, dans les 
cellules cancéreuses du cerveau. Enfi n, nos données peuvent être ajoutées à la li ttérature 
grand issante qui s uggère l'exploration de la Concanava line A comme une potentie ll e 
entité thérapeutique. 
SUMMARY 
G lioblastoma multiforme (GBM) is one of the most aggressive types of brain 
tumours, constituting l to 2% of a il adu lt tumours. Though relatively rare, GBMs have a 
dire prognosis and are very difficult to treat. The causes of GBMs are relative! y unknown 
making the study of the molecular pathologies that lead to this d isease important, as we il 
as enabling the development of more efficacious treatment strategies. A considerable 
obstac le in the treatment of GBMs, and in genera l, disorders of the central nervous 
system (CNS), is the abi lity to penetrate the blood-brain barrier (BB B) 
pharmacologically. Angiopep-2 is a short inert peptide that was designed as a drug 
delivery system: it is se lectively internali zed across the BBB in a low-density lipoprote in 
receptor-related protein 1 (LRP- 1 )-dependent manner. Thi s has a llowed for the successful 
development of drug molecules that are conjugated to Angiopep-2, allowing delivery to 
the brain. LRP-1 is a large receptor, present on the cell surface of BBB endothe lia l cell s, 
as weil as being expressed in brain and brain tumour cells. lt has many functions, 
including the internalization of extracel lular ligands. lt is a lso associated with ce ll 
survival and cell migration. ln addition to this, LRP-1 has been implicated in both cancer 
grade and phenotype. LRP- 1 express ion and function has already been shown to be 
regulated by Membrane Type 1 Matrix Metalloproteinase (MTI-MMP, also known as 
MMP-14). MT 1-MMP has been shown to be ab le to c leave LRP- 1, playing a rote in the 
regulation of LRP-1-mediated functions. In our research, we decided to explore MTI-
MMP regulation ofLRP- 1 in a glioma cellline, and see whether thi s would impact on the 
internalization of Angiopep-2, a therapeutic avenue which holds great promise in the 
treatment of GBM and other CNS disorders. We treated the GBM cell mode! , U87, with 
the plant lectin Concanavalin A (ConA), known to induce the activation and transcription 
of MTI-MMP, and found that there was rapid internalization and degradation of LRP- 1. 
However, through gene silencing of MTI-MMP and other known mediators of ConA-
signalling, as weil as the use of se lective inhibitors, we estab li shed that th is effect was not 
mediated by MTI-MMP, nor via a direct cell-ConA interaction. Knowing that ConA's 
effects involve disruption to the actin cytoskeleton, we selectively disrupted the actin and 
microtubule cytoskeleton and found that the effects on LRP-1 were due to disruption of 
the actin, and not microtubule, cytoskeleton. Furthermore, this internalization and 
degradation of LRP-1 led to a significant reduction in the capacity of U87 cells to 
internai ize a2Macroglobul in and Angiopep-2, a natural and synthetic ligand of LRP-1 , 
respectively. We conclude that actin cytoskeleton integrity is required for proper LRP-1 
cell surface functions. Furthermore, our data demonstrate the pivotai requirement of ce ll 
surface LRP-1 fu nctions in the vectori zed transport of therapeutic Angiopep 
bioconjugates into brain cancer cel ls. ln add ition, these data can be added to growing 
li terature base supporting the claim that ConA merits further study as a potential 
therapeutic entity. 
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1. Introduction 
Canceri sa patho logy where populations of ce Il s ga in a phenotype where they no 
longer fo llow the intricate and extensive mechani sms that regulate homeostas is. This 
enables non-homeostati c growth of certain cell s in an uninhibi ted manner. (Liotta & 
Kohn, 2001 ) This is a dynamic, mul ti-step process that in general takes many years to 
develop. A highly selecti ve process is required to overcome the innate mechanisms that 
inhibi t the occurrence of cancers. These cell s are highly proli ferati ve, and have often !ost 
cell-ce ll contact induced growth inhibition - they gain these phenotypes through: 
genomic; proteomic; post-translational; epigeneti c modifi cations that generate the highly 
compl ex alterations in cancerous ti ssues. (Hanahan & Wei nberg, 20 11 ) Hannah et a l. , in 
their seminal paper describe the ' hallmarks of cancer' ( 
Figure 1) - six characteri stics required for progress ion to the neoplasti c state. 
(Hanahan, Weinberg, & Francisco, 2000) However, as described by Lazebnik, these 
ha llmarks are also characteri sti cs of benign tumours, except for 'Tissue invas ion and 
metastas is ' . (Lazebnik, 2010) Thus, it is important to consider the use of the words 
' tumour ' and ' cancer' , as they are not interchangeable. This process of invasion is 
multi faceted and invo lves many steps that are interlinked and interdependent (F igure 2), 
which ultimately result in metastatic invas ion. lnitia lly, as bi omedical research began to 
understand the geneti c component of the di sease, interest was concentrated and hope was 
placed, in a simplistic view of sing le cel! lineages being responsible fo r the cancer 
phenomena - however, it is now understood that there is a very complex interplay 
between heterogeneous pre-cancerous populations, and non-cancerous, but assoc iated 
host cell s that provide an essential component to the development of a malignant 
pathology. This includes the induction of angiogenes is, modifi cation of the tumour 
environment, the recruitment of immune and stem ce ll s, and the conditioning of potential 
metastatic sites. (S iemann, Dietmar, 20 1 0) 
Evading 
apoptosis 
Sustained 
angiogenesis 
ilnsensitivity to 
anti-growth signais 
Tissue invasion 
& metastasis 
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Figure 1 T he acquired ' hall marks' of cancer. Cancer cel! genotypes invo lve the manifestati on of 
six essentia l a lteratio ns in cel! physio logy that co llecti vely di ctate mali gnant growth: self-
suffi ciency in growth signais, insensiti vity to grovvth-inhibitory signais, evasion of programmed 
cell death, limitless repl icative potential , sustained ang iogenesis, and tissue invasion and 
metastasis. Each of these physio logie changes- novel capab iliti es acq uired during tumour 
development- represents the successful breaching of an an ti cancer defence mechani sm hard wired 
into cell s and ti ssues . Adapted from ( Hanahan et al. , 2000) 
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Motility and Invasion 
Metastasla of 
metastases 
Figure 2 ' Cancer metastasis consists of sequentia l, interlinked, and selective steps. The outcome of each step is 
innuenced by the interaction of meta tatic cellul ar subpopul atio ns with ho meostatic factors. Each step of the 
metastatic cascade is potentially rate limiting such that fa ilure of a tumour cell to complete any step effectively 
impedes that portion of the process, th us, the interplay between the many factors is essential to understanding, 
and perhaps identifying the factors most innuentia l in the process of benign tumours becoming cancerous' . 
(Ta i madge & Fid ler, 20 1 0) 
1.1 Brain Turnours 
Brain tu mours are a relative! y rare di sorder, with an incidence of 2-10 cases per 
100,000 people, globally. (Bondy et al., 2008) The majority of de nova brain tu mours are 
of neuroepithelial origin, and are called g liomas. These are graded according to their 
aggress iveness, from 1 to IV. Grade IV gliomas, or glioblastoma multiforme (GBM), are 
the most common glioma, and the most aggress ive (Ohgaki & Kleihues, 2007) - GBM 
tumours represent only 1-2% of ali adult tumours however, they are ultimately 
untreatable. (Erpolat et al. , 2009)(Wen & Kesari, 2008) This has led to the dire prognosis 
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of this pathology - treatment strategies are ineffective ( despite surgi cal intervention 
extending li fe expectancy). The mean ti me from diagnos is to death w ith treatment is 14 
months, and the 5 year surviva l rate is 10%. (Bhujbal de Vos, & Ni clou, 201 4) The ir 
hi stopathological hall marks include substanti al vascularisation - GBMs being one of the 
most highly vascularised neoplasms (Visted & Lund-Johansen, 2003). ln addition to 
primary brain tumours, secondary metastases are a major challenge and common in 
breast, co lorectal , melanoma and Jung cancer. (Bhujbal et al. , 20 1 4) 
1.2 Glioblastomas 
The aetiology of GBM is re lative ly unknown, with only the exception of 
therape utic irradiation being assoc iated with an increased ri sk of malignancy. (V isted & 
Lund-Johansen, 2003) Associations with head injuries, foods containing N-nitroso 
compounds, occupat ional ri sk factors and e lectromagnetic fi elds have been inconclusive. 
(Wen & Kesari , 2008) However, there is sorne suggested ev idence of immunological 
factors contributing: atopic individuals having a reduced risk fo r g li oma development; 
patients with GBMs who have elevated IgE Jevels having an improved prognosis. 
lnteresting ly, only 5% of GBM cases have familial association. (Wen & Kesari , 2008) 
Bra in tumours, and many cancers in general , can be characteri sed by aberrant receptor 
tyrosi ne kinase (RTK) signalling. ln GBMs, malignant transformat ion can be attributed to 
growth factor signalling. Roughl y 90% of GBM tumours have aberrant RT K signa lling, 
with 45% involving the epidermal growth factor receptor (EGFR) fami ly of RTKs. 
(McLendon et a l. , 2008) RTKs have been targeted in severa! c linical trials, but have ali 
ultimately fai led to show any benefit as a treatment. (Johansson et a l. , 20 1 3) 
1.3 Treatment 
Standard treatment of GBM involves, as much where poss ible, tumour resection 
fo llowed by radiation therapy and temozolomide-based chemotherapy. (Kauer, 
Figueiredo, Hingtgen, & Shah, 20 12) Radiation and chemotherapy does improve !ife 
expectancy - 18.9 vs 9.8 months without, (Erpolat et a l. , 2009) however thi s is still far 
behind advances made in other cancer treatments, and the benefits of chemotherapy in 
GBM treatment are debated. (Sari n, 2009) Despite resection of the tumour being 
effective, nearly 100% of GBM cases are fata l, (Lesniak & Brem, 2004) with 80-90% 
recurrence of the tumour occurring within 2 cm of the resection cavity . (Bhujbal et al. , 
201 4) There are of course severa! factors that can be attributed to this phenomenon. 
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However, it is relative ly we il accepted that the biggest barriers to effective treatment of 
the residual , infiltrating cells, involves, among others: poor therapeutic access to CNS 
because of the blood brain barrier (BBB)" (Muldoon et al., 2007) vascular dysfunction at 
the tumour; (Jain, Tong, & Munn, 2007) and, a short half-life of therapeutic molecules 
once in vivo. (Sarin, 2009) Pre-clinical studies have shown that the ineffectiveness of 
many treatment strategies can be attributed to poor BBB penetration. For example, the 
use of monoclonal antibodies against EGFRvlll in a murine mode! led to tumour 
shrinkage in subcutaneous melanomas but not in intracranial brain metastases due to poor 
BBB penetration. (J .H. Sampson, L.E. Crotty, S. Lee, G.E. Archer, D.M . Ash ley, C.J. 
Wikstrand, 2000; Lesniak & Brem, 2004) 
1.4 Therapeutic Barri ers Of The CNS 
One of the major obstacles in addressing pathologies of the CNS such as brain 
tumours ; HIY encephalopathies; epi lepsy; cerebrovascular disease; and 
neurodegenerative diseases), is achieving therapeutic concentrations of pharmacological 
agents within the CNS. (Misra, Ganesh, & Shahi wala, 2003) Severa! factors contribute to 
this phenomenon. Primarily, this is caused by the permeability of the BBB: due to its 
specialized function in protecting the CNS, which in the ensuing text wi ll be discussed, it 
is very difficult to select agents which are BBB-permeable. (Lesniak & Brem, 2004) 
There are also other substantia l factors, which are not limited to the CNS, that affect 
therapeutic concentrations at the desired site. Especially with chemotherapeutic agents, 
active transport out from tumour cells and BBB endothelial cells by efflux pumps such as 
P-glycoprotein results in diminished concentrations of the drug. (Schinkel et al., 1997) 
Furthermore, within the CNS there is a variance in drug vo lume distribution detennined 
by ce llular uptake, interactions with lipids and proteins, as weil as accumulation in 
subcellular compartments. (Muldoon et al. , 2007) With system ic delivery of agents, there 
is substantial plasma protein binding: for chemotherapeutic agents this can often be 90%, 
with only 10% free drug. However, this can be even higher: for example, the alkylating 
agent Chlormbuci l is 99% plasma protein bound. (Muldoon et al. , 2007) Another 
substantial barrier to effective targeting of cancer cells is the high tumoural interstitial 
pressure. This can often be above 50 mmHg; whereas the surrounding tissue will be at 2 
mmHg. (Muldoon et al. , 2007) This high interstitial pressure diminishes the transcapillary 
flow, sign ificant ly reducing the delivery of drugs to the tumour. This is likely caused by: 
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bl ood- vesse! leaki ness; i nterstitial fi brosis; contraction of the i nterstitial matrix mediated 
by stroma! fibrobl asts. (Heldin, Rubin, Pietras, & Ostman, 2004) 
1.5 The Blood Brain Barrier (BBB) 
The BBB acts to protect the CNS from fluctuations in the composition of the 
bl ood (hormones, amino ac ids, glucose, ce11ain toxins etc.). lt tightly regulates the 
passage of materi als across the CNS-cardiovascular interface through anatomical, 
physicochemi cal, and biochemical mechanisms. The neurovascul ar unit is the anatomical 
feature fo rming the BBB, found at the endothelial ce ll - brain capillary site (Figure 3), 
deri ving its properties from a speci alized basal membrane, perycites and astrocytic 
endfeet. These features co-operate to produce the BBB, and to tightly control the passage 
of molecules a cross the interface. The conti nuous ti ght j unctions th at j oi n the endothelial 
ce ll s in the brain capillari es limit the diffusion of molecules across the BBB (the major 
proteins invo lved in this are summari sed in Figure 4). The basal membrane provides 
structural support fo r the capillary and specifie proteins present in the basement 
membrane play a part in the development and establi shment of the BBB. (Obermeier, 
Da neman, & Ransohoff, 20 13) Astrocyti c foot processes release specifie factors and are 
necessary for the development of the BBB. Transport carriers fo r glucose and essential 
amino ac ids fac ilitate the movement of these solutes into the brain - neuronal cells are 
unable to synthesize these essential amino acids, it is taken up from the bl ood. Secondary 
transport systems appear to cause eftl ux of small molecules and non-essential amino 
acids from the brain to the blood. Sodium ion transporters on the luminal membrane and 
Na/K-ATPases and on the anti-luminal membrane account fo r the movement of sodium 
from the blood to the brain - the large number of mitochondria present in brain 
endotheli al ce ll s provide energy for the functionjng of these Na/K-ATPase. The major 
pathways fo r the movement of material into the CNS compartment (described in Figure 
5) include: paracellular routes for small water-soluble molecules; transcellular for lipid 
soluble molecules, transport protein-medi ated and receptor-mediated cellular 
internai ization and transport. 22- 25 
Dur" 
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Figure 3 Location of barrier sites in the CNS. Barriers are present at three main sites: the brain 
endothelium fo rming the blood- brain barrier (BBB) ( 1 ), the arachnoid epithelium (2) forming the 
middle layer of the meninges, and the choroid plex us epithelium (3), whi ch secretes cerebrospinal 
Auid (CSF) . At each site, the phys ica l barrier is caused by ti ght junctions that reduce the 
permeabili ty of the paracellular (i ntercellular cleft) pathway. Modified from. (A bbott, Réinnback, 
& Hansson, 2006) 
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Figure 4 'The maj or proteins associated with ti ghtjunctions (TJs) at the BBB are shown. The tight 
junction is embedded in a cholesterol-enriched region of the plasma membrane (shaded). Three 
integral proteins- claudin 1 and 2, occludin and junctional adhesion molecule (JAM)- form the 
tight j unction. Claudins make up the backbone of the TJ strands f01·ming dimers and bind 
homotypically to claudins on adjacent cells to produce the primary sea l of the TJ. Occludin 
functi ons as a dynamic regulatory protein. The tight junction also consists of severa! accessary 
proteins, which contribute to its structural support. The zonula occludens proteins (Z0-1 to 3) 
serve as recognition proteins for tight junctional placement and as a support structure for signal 
transduction proteins. AF6 is a Ras effector molecule associated with Z0-1 . 7H6 antigen is a 
phosphoprotein fou nd at tight junctions impermeab le to ions and molecules. Ci ngulin is a double-
stranded myosin-like protein thal bi nds preferentiall y to ZO proteins at the globular head and to 
other cingulin molecules at the globul ar tail. The primary cytoskeletal protein. actin , has known 
bind ing sites on ail of the ZO proteins·. (Nag, 2003) 
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Figure 5 ' Path ways across the blood- brain barri e r. A schemati c di agram of the endothe li al cells 
that fo rm the blood- brain barri er (BBB) and their associations with the peri vascul ar end feet of 
astrocytes. The main routes for molecul ar tra ffi c across the BBB are shown. A) Normall y, the tight 
junctions severely restrict penetratio n of water-so lubl e compo unds, including polar drugs. B) 
However, the large surface area of the lipid membranes of the endothelium offers an effecti ve 
diffusive route for lipid-so luble agents. C) The endothe lium contai ns transport proteins (carriers) 
fo r glucose, amino acids, purine bases, nucleosides, cho line and other substances. Sorne 
transporters are energy-dependent ( for example, P-glycoprotein) and act as effl ux transporters. 
AZT, azidothymidine. D) Certain proteins, such as insulin and transferrin, are taken up by specifi e 
receptor-medi ated endocytosis and transcytosis. E) Nati ve pl asma pro teins such as albumin are 
poorly transported, but cati oni zation can increase their uptake by adsorpti ve-medi ated endocytos is 
and transcytosis. Drug deli very across the brain endothe lium depends o n making use of pathways 
b- e; most CNS drugs enter via route b'. (Abbott et a l. , 2006) 
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1.6 The Cytoskeleton 
The cytoskeleton's role is integral to almost every cellular function: it is the 
structure that gives cells their shape, mediates the controlled movement of subcellular 
structures such as organelles, as weil as facilitating the organi sati on of cellular processes. 
(Al bert, B. , 201 0) The cytoskel eton consists of three major classes of molecules that 
di ffer in size and in prote in composition. Microtubules are the largest type of fil aments 
and they are composed of a protein cal led tubulin. Actin filaments are the smallest type 
and they are made of a protein call ed actin. lntermediate fil aments, as their name 
suggests, are mid-sized. (A lbert, B., 201 0) 
The actin cytoskeleton plays an integral role in the spatial order of interna! 
structures, providing mechanical forces and medi ating adherence of the cell , it provides 
the contractile forces as we il as linking mechanical stresses to biological responses. 
(Fischer & Fowler, 20 15) The actin cytoskeleton is also essential fo r the transport of 
cargos through the ce l! cytosol, as weil as the mediation of the internalization of 
extracellul ar cargos, and the creation of membrane vesicles. (Albert, B. , 2010) 
These structures also function, to a certain extent, as detectors for mechanical 
signais: crosstalk between the actin cytoskeleton and microtubule cytoskeleton plays a 
role in mediating the polarization of cells during di vision, morphological changes, as we il 
as migration. Thi s can be crucial for the development of ti ssues, as we il as the 
homeostatic balance between non-metastatic, and metastatic ce ll s. ln migrating ce ll s, 
growing microtubul es that reach into the leading edge promote Rac activation and the 
fo rmati on of short, branched F-actin for lamellipodia fo rmati on. ln essence, the ce l! can 
respond the extrinsic, phys ical eues that can be translated into biologica l responses, which 
lead to the fo rmation of the required structures. (A kJ1shi , Werni ke, & Piekny, 20 14) 
The cytoskeleton is also an integral component of ves icular traffi cking: during 
endocytosis, transport within the cel! and, exocytosis. (A lbert, B., 20 10) The cytoskeleton 
also plays an integra l part in modulating membrane curvature and tension. FUI1hermore, it 
is invo lved in the regul ation of clathrin coated pit internali sation: GPCRs interacting wi th 
the actin cytoskeleton regulating the rate of the internali sati on of cargos, as we il as 
perhaps, adding in the creati on of fo rces during dynamin fi ss ion. ln additi on, it has been 
Il 
suggested that the interplay between the cytoskeleton and the plasma membrane allows 
for mechanisms that facilitate internalisation of large volumes of membrane during, for 
example, pinocytosis or macropinocytosis. 
Metastatic disease, or the movement of cancer cells from one site to another, is a 
complex process, as previously described, which can also involve dramatic remodelling 
of the cytoskeleton. The various components of the cytoskeleton are highly integrated and 
the ir functions are weil orchestrated in normal , physiological cells. (Albert, B., 201 0) ln 
contrast, in metastatic pathologies, mutations and abnormal expression of cytoskeletal 
and cytoskeletal-associated proteins can play an important role in the abi li ty of cancer 
cells to metastasize, as weil as to resist treatment strategies. Studies on the role of actin 
and its interacting partners have highlighted key signalling pathways, such as the Rho 
GTPases (where they can mediate the formation of different types of F-actin that confer 
changes in cortical tension and contraction, and can be regulated by microtubules) and 
downstream effector proteins that, through the cytoskeleton, mediate tumour ce l! 
migration, invasion and metastasis . lmproved understanding of how the cytoskeleton and 
its interacting partners influence tumour cel! migration and metastasis has led to the 
development of novel therapeutics against aggressive and metastatic di sease. (F ife, 
McCarroll , & Kavallaris, 20 14) 
1. 7 Ma tri x Metalloproteinases (MMPs) 
The plethora and complexity of the acquired phenotypes that enable cellu lar 
transformation to neoplastic tumours are exquisitely complex- in some cases dependent, 
and others independent of one another. The invasive and metastatic ability of tumour 
cells, especially in GBM cases, contributes significantly to their morbidity and mortality . 
This gained phenotype is often as a result of deregulation of the relationship between the 
cel! and the extracellular matrix (ECM). This is a complex interaction involving proteases 
(main ly MMPs), their inhibitors and a plethora of signalling molecules that orchestrate 
this delicate interaction. (Siemann, Dietmar, 2010) 
The MMPs are a family of zinc-dependent endopeptidases that are able to 
degrade nearly ali the components of the ECM including, but not limited t,o fibrillar and 
nonfibrillar co llagens, fibronectin , laminin and basement membrane proteoglycans. 
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(U iasov, Yi , Guo, Sarvaiya, & Cobbs, 20 14) as weil as other non-matrix substrates 
impl icated in tumour establi shment. The fam ily cons ists of more than 23 members, both 
secreted and membrane-anchored, that are synthesised as zymogens and many, furin-
activatable. (S iemann, Dietmar, 20 1 0) (Egeblad & Werb, 2002) 
The MMPs play a sign ificant role in the regul at ion of the tumour 
microenvironment. They are heavily involved in tissue remodelling, including specifie 
physiological processes such as ce ll migration and proliferation. (S iemann, 20 1 0) This 
involves the degradation of the ECM (the different MMPs being specifie for varying 
substrates), and also the re lease of cytokines and growth facto rs from degraded basement 
membrane. Of the MMPs, MMP-2 and -9, as weil as MTI-MMP, have been studied 
extensively due to the ir invo lvement in migration, invasion and metastas is (S iemann, 
Dietmar, 20 1 0). 
1.8 MTl-MMP 
MTJ-MMP is a transmembrane MMP, and the most extensively studied , that plays a 
major role in ce ll motility. Among its funct ions, it is often fou nd at the leading edge of 
migrating and invading cells- along with its inhibitor TIMP2, MTI-MMP, in a multi-
step process, is responsible fo r MMP-2 activation. (Sato et al. , 1994, Ries et al. , 2007) 
Together, these MMPs are able to target many substrates in the ECM , including œ il-
adhesion molecules such as aV integrin subunit precursor (MT I-MMP), lamininY (both) 
and CD44 (MT I-MMP) - both MMPs playing integral roles in angiogenes is and cell 
invas ion. (Egeblad & Werb, 2002; ltoh, 2006) To summarize, as shown in figure 6, MTI-
MMP 's major role in ECM proteolysis is amplified by its ability to activate MMP-2 (as 
weil as MMP-13) . This is coupled with the processing and degradation of many œ il-
adhesion molecules, with the release of ECM fragments that promote both growth and 
migration. (ltoh, 2006) 
MTI-MMP has been shown to play an integral role in angiogenes is, and is li ke ly 
linked to its ro le in tumorigenesis where its upregulation is invo lved in the formation of 
MTI-MMP-YEGFR2-Src complexes that result in the act ivation of Akt and mTOR 
(Eisenach et al. , 20 1 0). However, add ing to the comp lexity of its role is the result that in 
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MTI-MMP deficient mice, there is normal vascular formation. (Holmbeck et al. , 1999) 
Whether the functions of MTI-MMP, during development, can be compensated by other 
systems, or that the funct ion in vasulogensis of MTI-MMP become important following 
development in unknown . 
There are severa! other biological functions of MTl-MMP that merit mention. These 
include MTI-MMP ' s modulation of the inflammatory response of macrophages. MTI-
MMP can trigger the expression and activation of a phosphoinos itide 3-kinase d 
(PJ3Kd)/Akt/GSK3b s ignaling cascade which in tum, MT!- MMP-dependent PI3Kd 
activation reg ulates the immunoregulatory Mi-2/NuRD nucleosome remodeling complex 
that is responsible for contro lling macrophage immune responses. (Shimizu-Hirota et al. , 
20 12) MTI-MMP a lso regulates Notch signal ling to maintain normal B-cell development 
in bone marrow, which occurs through the cleavagee ofNotch ligand Delta-like 1, found 
on bone marrow stroma! cell s cel! surface. (Jin et al., 2011) 
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Figure 6 ' Bio logical activ ities of MT I-MM P (MT l-MM P) and their regul ation. MT I-MMP 
enhances ce l! mi gration and invasion by d irect ECM degrada tion, activation of proMMP-2 and 
proMMP- 13, CD44 and syndecan- 1 shedding, ER.K acti vati on, and laminin 5 processing. These 
activities are pos iti vely (+) and negati ve! y (-) regul ated by a vari ety of processes. Di sturbing one 
of the pos it ive regul ation pro cesses may be enough to inhi bit MT 1-M MP-dependent cel! 
mi gration ' . (I toh, 2006) 
1.9 MTl-MMP Targets 
As an MMP, MT I-MMP has a broad range of targets. ln it's function of 
pericellular proteolys is of ECM macromolecules. MT I-MMP degrades Coll agen 1, Il, Il ; 
Gelatin; Laminin 1 and IV ; Fibronectin; Vitronectin; Aggrecan; Fibrin; Nidogen; 
Perlecan; Lumican. Furthermore, MT I-MMP is able to interact with ce ll surface proteins 
on nearby cell s. Here, it is able interact with targets such as: CD44; Transglutaminase; 
LRP-1 ; Syndecan-1 ; Extrace llular Signal Regulated Kinase (ERK) as weil as YEGF. 
(Uiasov et al. , 2014) Due to the plethora of poss ible interactions that MT I-MMP, and the 
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MMPs, in general , have, a developed and integrated knowledge of these functions wi ll 
help better direct MMP inhibitor therapies that have, thus far, failed. (Egeblad & Werb, 
2002) 
1.10 LRP-1 
LRP-1 is a member of the LDL receptor fami ly of endocytic receptors (Figure 7) 
and is formed of two subunits, one extracellular of 515 kDa; one cytoplasmic of 85 kDa. 
The mature receptor is generated from its pro-form through cleavage of the 600 kDa 
peptide by Furin. (Wi llnow et al. , 1996) 
This fami ly contains severa! functionally dynamic receptors involved in the 
cellular internalization of many circulating ligands. LJU>-1 is found predominantly in the 
CNS and liver where it plays a significant role: specifie for many ligands relevant to 
cholesterol homeostasis, it is also involved in the clearance of proteins, especially within 
the CNS. On binding to ligands, LJU>-1 and its ligands undergo clathrin-mediated 
endocytosis, where the ligand is further processed or degraded in lysosomes - LRP-1 is 
then recycled back to the ce ll surface or to other intracellular compartments. (Nubile, 
2007) 
LRP-1 is one of three LDLRs that contain NPXY motifs - it has two within its 
intracellular 85 kDa signalling subunit. LRP-1 plays a role in intra-cellular signalling and 
has been found to be implicated in many essential functions (KO in mice being 
embryonically lethal). (A. P. Lillis, Van Duyn, Murphy-Ullrich, & Strickland, 2008) For 
example, LJU>- 1 plays an important role as a pro-survival signalling element; it has been 
implicated in varying fonns of Alzheimer 's disease (having both positive and negative 
effects). (Nubile, 2007) 
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Figure 7 The LDLR family of receptors. 'The structural organization of the low-density 
lipoprotein receptor (LDLR) family members. Ali of the receptors are ty pe 1 receptors that contain 
a single membrane-spanning domain and a relati vely short cytoplasmic tail. The extracellular 
regions ofthese receptors contain three characteristic modules: li gand-binding repeats (also ca lled 
complement-type repeats), epidermal growth factor (EGF) repeats and YWTD-containing ~­
propeller domain s. The furin cleavage sites in LDLR-related protein 1 (LRP 1) and LRP 1 B are 
indicated by arrows. The four clusters of ligand-binding repeats in LRP 1 are label led ( l- I V). 
1-lighlighted in blue are the two extra sequences in LRP IB (compared with LRP I ). which are 
encoded by two extra exons: a ligand-binding repeat in the fourth ligand-binding domain and a 33 -
amino acid insert in the cytoplasmic tail. LRP5, LRP6 and sortilin-related receptor with A -type 
repeats (SORLA; also known as ORL 1 and LR Il ) are di tant members of the fami ly with 
atypical structural arrangements. Severa! other LDLR fami ly members with poorly defined 
fu ncti ons, including LRP3 , LRP9 and LRPI2 ' . (Bu, 2009) 
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ln cancers, the literature suggests both positive and negative effects of LRP-1 
status and function. lnitia lly, it appeared that LRP-1 had protective properties in the 
malignant phenotype, namely due to it's ability to clear the extracellul ar compartment of 
proteases. LRP-1 expression has also been found to be downregulated in the most 
malignant gliomas. However, in the past decades, studies have emerged suggesting that 
LRP-1 does in fact play a significant role in the malignant phenotype of cancer cel ls. 
lt has been shown that LRP-1 is tethered to the actin network and focal adhesions 
s ites; it was suggested that through this interaction, activati ng ERK signalling pathways 
and inhibiting JNK pathways, LRP-1 contributes to the cancer cel ! adhesive state 
favouring invasion. Furthermore, it was demonstrated that LRP-1-dependent MAPK 
signalling contributes to cytoskeleton architecture organisation, and the mediation of 
adhesive complex turnover. (Langlois et al. , 201 0) An example of the LRP- 1 paradox is, 
despite LRP-1 ' s role in clearing extracellul ar proteases that it has been shown to be 
involved in the induction of both MMP-2 and 9, albeit in endometrial explants and not 
cancer cell models. (Se l vais et al. , 2009) 
LRP- 1 is involved in ce l! survival, proliferation and focal adhesion complex 
composition, and turnover (8 Langlois, Emonard, Martiny, & Dedieu, 2009) - LRP-1 
being found on the invas ive front of invading cancer ce ll s. Furthermore novel 
interactions with the CD44 protein implicate LRP-1 in both its internalization and 
recycling, with LRP-1 1 CD44 complexes being found at the migratory front of carcinoma 
cells. (Perrot et al. , 20 12) There are severa! studies demonstrating that LRP-1 blockade 
reduces the invasive phenotype of cancer cel! models. ln both carcrinoma and GBM cell s 
LRP-1 si lencing has shown to reduce ce li invasion and migratory capacity, des pite 
elevated levels of MMP-2 in the extrace llular compartment. (Dedieu et a l. , 2008) 
Another interesting function of LRP-1 , wh ich may have implications in the 
malignant phenotype, is its roles in cell survival: LRP- 1, in primary neurones, was 
demonstrated to have an anti-apoptopic function where it is able to regulate the insulin 
receptor, as we il as the Akt survival pathway (Fuentealba, Liu, Kanekiyo, Zhang, & Bu, 
2009) (an affected target in ConA mediated ce l! death). LRP- 1 also plays a significant 
role in the vascu lar system, where it is weil studied. Recently a study has shown the 
potential of LRP-1 to contribute to the recruitment of monocytes to the tumour 
18 
compartment, th at in tu rn are attributed with the a bi 1 ity to promote vascularisation of the 
tumour. (Staudt et al. , 201 3) 
ln ali , LRP-1 's roles are yet to be fully characterised and understood. However, it 
is evident that due to the plethora of rotes it has, and can have, in a potentially 
environment 1 compartment specifie manner, further understanding of its regulation have 
far-reaching implications. One can speculate that LRP-1 does play a role in the transition 
from benign to malignant tumour, and that it contributes to this phenotype in multiple 
ways. 
1.11 Na tura! and Synthetic Ligands Of LRP-1 ; Vectorized Drug 
Delivery 
As described previous ly, LRP-1 has many functions including lipoprotein 
metabolism, degradation of proteases, activation of lysosomal enzymes and cellular entry 
of bacterial toxins and viruses. This broad role is reflected in the number of ligands it 
binds, with LRP-1 being reported to bind up to 60 ligands, including: apolipoprotein E-
enriched lipoproteins (chylomicron and YLDL remnants), a2Macroglobulin, uPA 
uPA/PAI-1 , neuroserpin, neuroserpin/tPA complexes, MMP-9, MMP-13 , MMP-2, HIV 
Tat protein, as weil as severa! growth factors, to name a few. (Li llis, Mikhailenko, & 
Strickland, 2005) 
Synthetic ligands of LRP-1 have been developed for the vectorized delivery of 
drugs. Angiopep-2 is a 19 amino acid peptide whose sequence is derived from the kunitz 
domain of aprotinin (and other peptides that are substrates for BBB tran cytosis) that is 
se lectively transported from the blood to the CNS compartment. lt was developed with 
the aim of providing a delivery vehicle for pharmacological agents that are otherwise 
excluded from the CNS compartment by BBB selectivity. (Demeule et al. , 2008) 
Angiopep-2 has been shawn to be transcytosed and internalized in a LRP-1 dependent 
manner, a receptor that is significantly expressed in brain endothelial cells, as weil as 
some brain tumours. Furthermore, it is not a substrate for the P-glycoprotein efflux pump, 
making it a highly attractive vehicle for molecules that are otherwise ejected from the 
CNS and tumour compartments. (Demeule et al. , 2008) Chemotherapeutic conjugates of 
Angiopep-2 have been demonstrated, both in vitro and in vivo, to be as effective in killing 
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tumour ce ll s - as weil as showing improved BBB penetration and increased tumour 
penetration - as un-conjugated forms. This includes species conjugated to Doxorubicin, 
Nocodazo le and Pac litaxel. (Bertrand et a l. , 20 Il ; Ché et al. , 201 0) Ang iopep conjugates 
are currently in clinica l-phase tri als, and appearing to be effi cacious: the paclitaxe l 
conj ugate showing promi sing results fo r breast cancer pati ents with secondary brain 
metastases. 
1.12 The Proprotein Convertase Furin 
Furin is a ubiquitously expressed protein that mediates the proteolytic maturation, 
by cleavage, of proprotein substrates in the secretory pathway. Though not a substantial 
topic in thi s thesis, it is germane to di scuss as both MT I-MMP and LRP-1 , who both 
contain the consensus site that furin cleaves (positioned after the carboxy-termina l 
arginine residue in the sequence - Arg- X- Lys/Arg- Arg - ), undergo Furin-mediated 
proteolyti c maturation. On its di scovery, Furin was thought to be a housekeeping protein, 
but has now been shown to have many roles and play an integra l ro le in both normal 
phys io logy and pathology. Furin is a 794 amino ac id peptide that resides predominantly 
in the trans-golgi network - its location being determined by s ignalling sequences in its 
cytoplasmic domain. The 83 amino acid pro-domain aids the peptide in its folding and 
acti vati on. This process of maturation occurs in a similar way to that of F urin ' s actions on 
other proproteins - it is autoacti vated in a compartment and pH spec ifie manner, using its 
' measure once, eut twice' rule. (Thomas, 2002) Furin is an essential protein in 
embryogenes is and homeostasis, as weil as being implicated in some major pathologies. 
For example, Furin is the principa l endoprotease for the 16 kDa ~-nerve growth factor, a 
critical playe r in neuronal ce l! death 1 survival ba lance, as we il as the transmembrane 
receptor Notch. Furin has a Iso implications in neurodegenerati ve di seases su ch as 
Alzheimer' s where it is involved in APP processing and the acti vation of both a - and ~­
secretase (members of the ADAM family of metaloprote iases) . (Thomas, 2002) 
Furthermore, Furin has been implicated in severa! cancers: upregulated in G BMs as we il 
as non-small ce l! lung carcinomas and squamous-cell carcinomas of the head and neck. 
(Mbi kay et al. , 1997) Furin is able to increase the mal ignancy of tu mours through its 
abili ty to activate MT I-MMP, whjch, in turn, via MMP-2, increases degradation of the 
ECM (depicted in Figure 8). Furin, in vitro, has been targeted pharmaco logicall y, where 
------------------------ ~------- - - -------------------- - -----
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its inhibition resulted in decreased ce l! moti lity and invas iveness in CHO and HT I080 
ce l! li nes. (Coppola et al. , 2008) 
FURJN 
pro MT1· MP 
MM 2~ 
Figure 8 Furi n (scissors in figure) is involved in the maturation of MT I-MMP, leading to a 
subseq uent increase in MMP-2 activa ti on, contri but ing to the metastatic phenotype of tumours. 
Adapted from. (Thomas, 2002) 
1.13 Plant Lectins 
Plant lectins are a fa mily ofCa2+/Mn2+- dependent carbohydrate binding proteins 
that are able to bind selecti ve ly and reversibly to free sugars on glycoproteins and 
glycolipids. (Vij ayan & Chandra, 1999) The speci fi city of the binding has lead to the 
class ifica tion of the lectins into 12 famili es. Over the past 20 years the lectins have been 
used to label and identify malignant vs beni gn tumours, evaluating the glycosylation state 
of malignancies (Mody, Joshi , & Chaney, 1995) and recently, their introduction into 
mi croarrays fo r high throughput analys is of protein glycosylation. (Z. Liu, Luo, Zhou, & 
Zhang, 20 13) Furthermore, increased interest has been placed in the anti -tumour 
properties exhibited by these lectins. For exampl e, they have apoptopic and autophagie 
inducing properties (the program med ce l! death signalli ng network illustrated in figure 9) 
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, (Zhang, Chen, Ouyang, Cheng, & Liu, 20 12) as weil as anti-ang iogenic. (Li, Yu, Xu, & 
Bao, 20 1 1 )'(Z. Liu et a l., 20 13) 
T here is a substantial volume of literature reporting the multiple effects of the 
plant lectins on cancers throughout the tissues of the body. Thi s includes severa! reports 
on the induction of apoptop ic cel! death induced by the lectins ConA, Polygonatum 
cyrtonema lectin and Mistletoe lectins. 
1.14 Concanavalin A 
ConA has been reported to induce both the extrinsic (Fas fam ily of death 
receports dependent) and the intrinsic (mitochondrial dependent) pathways of apoptopic 
ce l! death. (Z. Liu et al. , 20 13) For example, apoptosis via the intrinsic pathway has been 
reported in both human melanoma A375 ce ll s (B. Liu et a l. , 2009) and hepatoce llul ar 
carcinoma HepG2 cell s; (Zhongyu Liu, Li , Ding, & Yang, 20 10). Furthermore, in U87 
GBM cell s, it has been shown to up-regulate COX-2 expression, as weil as down-regulate 
Akt expression via lKK!NFkB-dependent pathways. (Pratt et a l. , 20 12) ConA induces 
apoptosis by inhibiting the Akt survival pathways as weil as activating FoxOia-Bim 
signalling in both ovarian and Li-Fraumeni syndrome cell s. (Z. Liu et a l. , 2013) 
ConA has also been shown to induce autophagie cell death via a BCL-
2/adenovirus EIB 19kDa-interacting protein 3 (BNIP-3) - mediated pathway. (Lei & 
Chang, 2009a) The mechanisms of ConA-induced ce ll death are varied (ConA ' s mutli-
faceted effects resu lting from various interacti ons, and modulations of a host of 
pathways) . (Li et a l. , 20 Il ) One mechani sm includes the association of ConA with 
mannose moieties at the plasma membrane, c lathrin-dependent internali zation to 
mitochondria and the initiation of autophagie cel! death. (Le i & Chang, 2009b) 
Furthermore, autophagy induced by ConA can be abrogated through the si lencing 
of MT l -MMP; though not by catalytic inhibition. (Pratt et a l. , 20 12) This suggests that 
MT I-MMP-mediated ConA- induced autophagy is signall ed, in the case of MTl-MMP, 
via the non-catalytic, cytoplasmic domain. (Pratt et al. , 20 12) Another interesti ng 
property of the plant lectins, especially ofConA, is the abi li ty to perturb the cytoskeleton. 
(V ijayan & Chand ra, 1999) 
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Interestingly, severa! of the cellular effects induced by Concanavalin A (ConA) 
are mediated, in part via MTI -MMP. Thi s includes MTI-MMP-mediated-MMP-2 
acti vati on; COX-2 induction, independent of the MT I-MMP catalytic domain; MTI-
MMP acti vation and transcri ption; the induction of autophagy biomarkers via MT I-
MMP 's cytoplasmi c signalling domain. (A kla, Pratt, & Annabi , 20 12; Annabi et al. , 
2009; Annabi et al. , 20 14; Pratt, Roy, & Annabi , 20 12; Si na et al., 20 1 0) Furthermore, of 
interest, is the abil ity of MTI-MMP to cleave LRP-1 in malignant ce lls- MT I-MMP 
acting as a ' sheddase ', leading to the N-terminal being shed into the extracellular milieu. 
(Rozanov et al. , 2004) 
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2 Hypothesis 
LRP-1 is a crucial player in GBM biology and a target for GBM treatments (as 
weil as other CNS di sorders). lt also plays an integral ro le in both phys iology, and the 
pathology of severa! diseases. As it has begun to be studied in more depth, reports are 
emerging showing a direct link to the cytoskeleton. Given thi s, further understanding of 
its regulation is certain ly pertinent for our co llective understanding. Within our group, 
MTI-MMP has been extensively studied, and has been shown in severa! other groups to 
be able to regulate LRP-1 expression. The plant lectin ConA presents as an entity with 
therapeutic potential , but its ab ili ty to induce the activation and transcription of MTl-
MMP (alongside other we il characterised effects, such as its abi lity to di srupts the 
ctyoskeleton), presents it as a useful tool to explore and investigate severa! potential 
cellular events that may impact on LRP-1 . Thus, whether ConA is able to modulate LRP-
1 in GBM cells, and affect the internalization of LRP-1 li gands, is of interest. 
Furthermore, given MTl-MMP's role in the GBM phenotype (as weil as other 
malignancies), further probing its effects, linked to the malignant processes that can be 
modelled with ConA, wi ll contribute to our understanding of the phenotypic 
transformation essential for transition to malignancy. 
Hypothesis: Treating U87 cells with ConA at a concentration able to induce 
MTl-MMP activation wi ll lead to MT 1-MMP mediated proteolytic process ing of LRP-1. 
The process ing of LRP-1 wi ll in turn lead to a reduced capacity of LRP- 1-Iigand 
internai ization. 
2.1 Aims and Objectives 
• Further characterise ConA mediated effects in U87 cells - specifically MTl-
MMP processing and MTI-MMP mediated events 
• Explore the role of ConA and its effects on MTI-MMP 111 LRP- 1-dependent 
vectorized drug del ivery 
Chapter II 
3 Results 
Publi hed as: Nanni et al. Impact of Concanavalin-A-Mediated Cytoskeleton Disruption 
on Low-Density Lipoprotein Receptor-Related Protein-1 lnternali zation and Ce ll Surface 
Express ion in Glioblastomas. Biomarkers in Cancer 2016:8 77-87 
doi : 1 0.4137/BIC.S38894. Published April 26 2016. 
Impact of Concanavalin-A-med iated cytoskeleton disruption on low-density 
lipoprotein receptor-related protein-1 internalization and cel! surface expression in 
g l iob lastomas 
Samuel Burke Nanni , Jonathan Pratt, David Beauchemin, Khadidja Haidara and 
Borhane Annabi 
From the Laboratoire d ' Oncolog ie Moléculaire, Centre de recherche BIOMED, 
Département de Chimie, Université du Québec à Montréal , Quebec, Canada 
Running title : LRP-1 expression is decreased upon cytoskeleton disruption 
Correspondence should be directed to : Borhane Annabi , Laboratoire d'Oncologie 
Moléculaire, Université du Québec à Montréal , C.P. 8888, Suce. Centre-ville, Montréal, 
Québec, Canada, H3C 3P8; Phone : (5 14) 987-3000 ext 7610; Fax: (5 14) 987-0246; E-
mail : annabi.borhane@uqam.ca 
Keywords: Gli oblastoma, Brain cancer, LRP-1 , Concanavalin-A, Cytoskeleton 
3.1 Summary 
The low-density lipoprotein receptor-related protein 1 (L RP-1 ) is a multiligand 
endocytic receptor which plays a pivotai ro le in controlling cytoskeleton dynamics during 
cancer ce ll migration. lts rapid endocytosis further all ows efficient clearance of 
extracellular ligands. Concanavalin-A (ConA) is a lectin used to trigger in vitro 
physiological cellular processes including cytoki nes secretion, nitric oxide production, 
and T lymphocytes activat ion. Given that ConA exe1is pa1i of its effects through 
cytoskeleton remodeling, we questioned whether it affected LRP-1 expression, 
intrace llular trafticking, and cell surface function in grade IV U87 glioblastoma cells. 
Us ing fl ow cytometry and confocal microscopy, we found that lo of the cel! surface 
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600-kDa mature form of LRP-1 occurs upon ConA treatment. Consequently, 
internalization of the physiological 2-Macroglobulin and of the synthetic Angiopep-2 
ligands of LRP-1 was a Iso decreased. Silencing of known mediators of ConA, such as the 
membrane type- ! matrix metalloproteinase, and the Toll -like receptors (TLR)-2 and 
TLR-6, was unable to rescue ConA-mediated LRP-1 expression decrease, implying that 
the loss of LRP-1 was independent of cel! surface relayed signaling. The ConA-mediated 
reduction in LRP-1 expression was emulated by the acti n-cytoskeleton disrupting agent 
Cytochalasin-D, but not by the microtubule inhibitor Nocodazole, and required both 
lysosomal- and ubiquitin-proteasome system-med iated degradation. Our study implies 
that acti n cytoske leton integrity is required for proper LRP-1 cel ! surface functions , and 
that impaired trafficking leads to specia li zed compartmentation and degradation. Our data 
also strengthen the biomarker role of cel! surface LRP-1 funct ions in the vectorized 
transport of therapeutic Angiopep bioconjugates into brain cancer cell s. 
3.2 Introduction 
Low density lipoprotein receptor-related protein 1 (LRP- 1) is a member of the LDL 
receptor fami ly of endocytic receptors formed of one extracellular 515 kDa subunit, and 
one cytoplasm ic 85 kDa subunit; 1 the mature receptor having been generated by the 
cleavage of a 600 kDa propeptide by Furin .2 The LRP family contains severa! 
functionally dynamic receptors involved in the cellular internalization of more than 40 
circu lating physiological ligands, including apolipoprotein E3, a2-Macroglobul in4, factor 
Vlll 5, lipoproteins6 and Amyloid-~. 7 Once ligand is bound, the LRP-1 / Iigand complex 
undergoes clathrin-med iated endocytosis in order that the ligand be further targeted 
withi n specialized intracellular compartments.8 Disruption of the LRP-1 gene in mice was 
found to be embryonically lethal , presumably because LRP-1 transduces intracellular 
signal ling and is involved in many essential functions. 9 
Over the past few decades, it has emerged that LRP-1 plays a significant role in the 
malignant phenotype of brain cancer ce ll s, where it is tethered to the actin network and 
focal adhesion sites.10 Through LRP !-dependent ac tin network remodel ing, the activating 
ERK and inhibiting JNK s ignal ling pathways contribute to the adhesive states of cancer 
ce li s which favor invasion. 11 lntriguingly, both positive and negative effects of the LRP-1 
status and function have been reported for cancer cells. LRP-1 displayed protective 
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properties in the CNS malignant phenotype, due to its abi lity to clear the extrace llular 
compartment of proteases. 12 The status of LRP-1 expression was also assessed in human 
glioma celllines 13, in in vivo glioblastomas 1\ and was found to be particularly elevated in 
U87 glioblastoma cell s15 as weil as CDI33+ pediatrie brain tumor cells.4 Severa! studies 
have also demonstrated that LRP-1 blockade reduced the invasive phenotype in numerous 
cancer ce ll models. 16 In glioblastoma ce ll s, LRP-1 si lencing reduced cel! invasion and 
migration abilities, despite elevated levels of MMP-2 in the extracellular compar1ment. 16 
Furthermore, its cel! surface interactions with the CD44 protein implicated LRP-1 in both 
internalization and recycling, with LRP-1 /CD44 complexes being fou nd at the migra tory 
front of carcinoma cells. 17 This association of LRP-1 compartmentation at the leading 
edge of migrating/invading cancer cells is relevant for its role in brain tumor 
development, and understanding of its ce l! surface expression will be crucial fo r the 
development of fu ture therapeutic strategies. lnterestingly, both LRP-1 and CD44 are 
cleaved by MT1-MMP,18•19 a transmembrane matrix metalloproteinase that plays a 
fundamental role in cel! motility. 20 Regulation of the invas ive phenotype of glioma cells 
involving a MT1-MMP/CD44/Caveolin-l interaction has been described2 1'22 through, in 
part, its rapid trafficking/recycling to the plasma membrane from trans-Golgi 
network!endosome storage compartments. 23 
Recently, the ligand internalization functions and recycling of LRP-1 to the cell 
surface have been exploited for the vectorized transport of synthetic cargo peptides, 
termed Angiopep, through the blood-brain barrier (BBB) and to the brain.24•25 Th is 
successful strategy led to the design of receptor-mediated internalization strategies 
through high brain permeable anticancer drugs such as paclitaxei-A ngiopep bioconjugates 
to gliomas?6-29 How cytoskeletal remodeling alters LRP-1 cel! surface availability and 
functions in ligand internalization have not yet been explored . Here, we used 
Concanavalin-A (ConA), a lectin regulating MTI-MMP ce l! surface proteolyt ic 
funct ions30•3 1 as weil as MTl-MMP catalyt ic independent inflammation and autophagy 
cel! signaling/ 2·33 to trigger molecular alterations of the cytoskeleton34'35 and assessed its 
impact on LRP-1 1 igand i nternal ization functions. 
3.3 Experimental Procedures 
Materials Electrophores is reagents were purchased from Bio-Rad 
(M ississauga, ON). HyGLO chemi luminescent HRP antibody detection reagents 
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were from Denville Scientific lnc. (Rockford, IL) . Micro bic inchoninic ac id 
protein assay reagents were from Pierce (USA). T he MMP inhibitor Jlomastat and 
the anti-LRP-1 light chain mAb (5A6) were purchased from EMD Millipore 
(Etobicoke, ON). A ngiopep-2 and a2-Macroglobulin were gifts from Angiochem 
Inc (Montreal, QC) . The antibody aga inst murine LRP Heavy Chain (8G 1) was 
from Calb iochem (San Diego, CA), the anti-COX-2 antibody (61 0203) was from 
BD Biosc iences (San Jose, CA), and the anti-GAPDH (Ab8245) and anti-
Ubiquitin (Ab7780) antibodies were from Abcam (Toronto, ON). The R-
phycoerythrin (PE)-conjugated mouse antibodi es against human CD91 and IgG 1 
K Isotype were from BD Biosc iences (Mississauga, ON). Horseradish perox idase-
conjugated donkey anti-rabbit and anti-mouse IgG secondary antibodies were 
from Jackson lmmunoResearch (West Grave, PA). T he anti-MT1-MMP hinge 
region antibody (M3927), Concanava lin-A, Cytochalas in-0, Nocodazo le, Furin 
inhibi tor ll, Tofacitinib, SB203580, PP2, UO 126, Acetyl- 1 1-keto-beta-boswellic 
ac id, sodium dodecylsul fate (SOS) and bov ine serum albumin (BSA) were from 
Sigma-Aldrich (Oakville, ON). 
Cel/ culture : The human U87 gli oblastoma cell line (American Type Culture 
Co llection, HTB-14) was ma inta ined in Eagle 's M inimum Essential Medium 
(EMEM, Wisent, 320-006CL) containing 10% (v/v) calf serum (HyCione 
Laboratories, SH30541 .03), 1 mM sodium pyruvate (S igma-Aldrich Canada, 
P2256), 100 units/ml penicillin and lOO mg/ml streptomyc in (Wisent, 250-202-
EL). Cell s were incubated at 37°C with 95% air and 5% C0 2. 
Total RNA isolation, eDNA synthesis and real-time quantitative RT-PCR : 
Total RN A was extracted from cell monolayers using TriZo l reagent (Li fe 
Technologies, 15596-018). For eDNA synthes is, 2 1-lg of total RN A were reverse-
transcr ibed using a high capac ity eDN A reverse transcription kit (Applied 
Biosystems, 4368814). eDNA was stored at -80°C prior to PCR. Gene express ion 
was quantified by real-t ime quantitative PCR using iQ Sso Fast EvaGreen 
Supermix (Bio-Rad). DNA amplification was carried out usin g a CFX connect 
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Reai-Tim e System (Bio-Rad) and product detection was perform ed by measuring 
binding of the fluorescent dye EvaGreen to double-stranded DNA . The 
QuantiTect primer sets were provided by QIAGEN : LRP1 (Hs_LRP1 _ 1_ SG 
QT000255 36), MTI-MMP (Hs_Mmp14_ 1_ SG QT00001533), TLR-2 
(Hs_ T LR2_ 1_ SG, QT00236131 ), TLR-6 (Hs_TLR6_ 1_ SG, QT00216272), 
GAPDH (Hs_GA PDH_2_SG QT011 92646) and ~-actin (Hs_Actb_2_SG 
QTOI 680476) . The relati ve quantities of target gene mRN A compared aga inst two 
interna i contro ls, GA PDH and ~-actin RN A, were measured by fo ll owing a L'.CT 
method employing an amplification plot (flu orescence signal vs. cycle number). 
The di fference (L'.CT) between the mean va lues in the triplicate sam pies of target 
gene and those of GA PDH and ~-actin mRNAs were ca lculated by th e C FX 
manager Software version 2.1 (Bio-Rad) and the relative quantifi ed value (RQV) 
was expressed as 2-ôCT· 
Transf ection method and RNA interference : Cell s were transiently 
transfected w ith 10 nM siRNA against MT 1-MMP (Hs_ MMPI4_6 HP validated 
siRNA; QIAGEN SI0364884 1), TLR-2 (HS_TLR2_ 1_ SG Q1A GEN 
QT00236 13 1), T LR-6 (HSTLR6_ 1_SG Q LA GEN QT002 16272), or scrambled 
sequences (A II Sta rs Negati ve Contro l s iRNA; QIAGEN, 10272 81 ) using 
Lipofectamine 2000 (Invitrogen, 1 1 668) . Every specifi e gene knockdown was 
eva luated by qRT-PCR as described above. 
Ge/afin zymograplty : Gelatin zymography was used to assess the extrace llular 
levels of proMMP-2 and MMP-2 activities. Briefl y, an a liquot (20 ) ..tl) of the 
culture medium was subj ected to SDS-po lyacrylamide gel e lectrophoresis (S OS-
PAGE) in a gel conta ining 0.1 mg/m 1 ge latin (S igma-A ldrich Canada, G2625) . 
T he gels were then incubated in 2 .5% Triton X-1 00 (Bioshop, TRX506.500) and 
rinsed in de io nized di stilled water. Ge ls were further incubated at 37°C fo r 20 
hours in 20 mM NaC I, 5 mM CaCI2, 0.02% Brij-35 , 50 mM T ris- HCI buffer, pH 
7.6 and then sta ined w ith 0.1 % Coomass ie Brilliant blue R-250 (Bioshop, 
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CBB250) and destained in 10% acetic acid, 30% methanol in water. Gelatinolytic 
activity was detected as unstained bands on a blue background. 
Immunoblotting procedures : Following treatments or transfection, U87 cells 
were washed with PBS and lysed with lysis buffer (50 mM Tris-HCI, pH 7.4, 120 
mM NaCI , 5 mM EDTA, 0.5% Nonidet P-40, 0.1% Triton) in the presence of 
phosphatase and protease inhibitors on ice for 30 minutes. Cell debris was 
pelleted by centrifugation for 10 min at high speed. Prote in concentration was 
quantified using a micro bicinchoninic acid protein assay kit (Thermo Fisher 
Scientific Inc) . Proteins (30 Dg) from control and treated cells were separated by 
SDS-PAGE. After electrophoresis, proteins were electrotransferred to 
polyvinylidene difluoride membranes which were then blocked for 1 hour at room 
temperature with 5% non-fat dry milk in Tris-buffered saline (150 mM NaCI , 20 
mM Tris- HCI , pH 7.5) containing 0.3% Tween-20 (TBST; Bioshop, TWN51 0-
500). Membranes were further washed in TBST and incubated with the indicated 
primary antibodies (1 / 1,000 dilution) in TBST containing 3% bovine serum 
album in and 0.1% sodium azide (Sigma-Aldrich Canada, S2002), followed by a 1 
hour inc ubation with horseradish peroxidase-conjugated donkey anti-rabbit 
(Jackson lmmunoResearch Laboratories, 711-035-152) or goat anti-mouse IgG 
(Jackson lmmunoResearch Laboratories, 115-035-062) at 1/2,500 dilutions in 
TBST containing 5% non-fat dry milk. Immunoreactive material was visualized 
by enhanced chemiluminescence (Amersham Pharmacia Biotech, RPN3004, Baie 
d' Urfé, QC). 
Binding and uptake assays of Angiopep-2 and a2-Macroglobulin: Cells were 
incubated with 250 nM Alexa488-a2-Macroglobulin 1 Ringer HEPES or Alexa488-
Angiopep-2 1 Ringer-HEPES or Ringer-HEPES alone for 1 hour at 37°C in the 
dark and washed 3 times with PBS 1 BSA (5%) 1 EDTA (2 nM) . Fluorescence was 
then measured in the FLI-A channel using a C6 Accuri flow cytometer (BD 
Biosciences, Mississauga, ON). 
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Confoca/ fluorescent microscopy assays of Angiopep-2 uptake and LRP-1 
expression : Cell s were incubated with 50 nM A lexa488-Ang iopep-2 in EMEM 
without pheno l red for 18 hours at 37°C, 5% C02 . Ce ll s were fixed in 4% 
formaldehyde (F isher Sc ientific, Ottawa, ON) for 20 minutes. lmmunosta ining 
was performed under non-penneabiliz ing conditions for J hour with the anti-LRP 
Heavy Cha in antibody (2 !lg/ml) in 1% BSA 1 PBS 1 NaN3, followed by 
Rhodamine Red-X donkey anti-mouse lgG (Invitrogen, Burlington, ON). A 
so lution of 10 !lg/ml DAPI diluted in PBS was used to stain the nuclei. 
Fluorescence was then monitored by confoca l microscopy using a Nikon Eclipse 
T i confoca l microscope and NIS Elements software. 
LRP-1 cel/ surface immunophenotyping : Cell s were co llected and re-
suspended in a so luti on of binding buffer. Then, ce ll s were incubated with e ither a 
PE mouse a-human CD91 or a mouse lgG 1 K lsotype control antibody for 1 hour 
at room tem perature in the dark. Cell s were washed 3 times with PBS. 
Fluorescence was then examined by fl ow cytometry in the FL2-A channel w ith a 
C6 Accuri . T he results obtained were quantified as the di fference between the 
geometr ie mean of LRP-1-PE and PE isotype contro l antibodies. 
Fluorescent microscopy : U87 cell s were seeded onto coverslips where they 
were treated w ith either Concanavalin-A, Cytochalasin-0 or Nocodazole. 
Subsequently, cells were e ither incubated and/or immunolabe lled followed by 
fixation. Images were acq uired using a Nikon Eclipse Ti confocal microscope and 
NIS Elements software. Images were then deconvo luted and, where indicated, 
co localisat ion analys is was carried out w ith AutoQuant X software. 
Statistical data analysis: Data are representat ive of three or more independent 
experiments. Statistical significance was assessed us ing Student's unpaired t-test. 
Probability va lues of less than 0.05 were considered significant and an aster isk (*) 
identifies such significance in the figures. 
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3.4 Results 
Cytoskeleton remodelling alters LRP-1 trafficking and cel/ surface expression. The 
lectin Concanavalin-A (ConA) was used to investigate whether cytoskeleton remodelling 
affected LRP-1 trafficking and recycling process to the ce ll surface in U87 g lioblastoma 
cell s. While untreated cell s expressed basallevels of MTI-MMP a nd of the 85-kDa LRP-
1 subunit, ConA-activated U87 cell s resulted in a loss of the 85-kDa transmembrane 
LRP- 1 subunit from whole ce ll lysates upon a 24 hours dose-response with ConA 
(Fig. l A) . As expected, ConA treatment a lso led to the induction of cyclooxygenase 
(COX)-2 expression3 1•32 and was corre lated with both MTI-MMP proteolytic processing 
into its 43-kDa species, and with proMMP-2 activation (F ig.l A). 30•3 1•36 Densitometric 
analys is of immunoblots showed that LRP-1 decrease in expression correlated with the 
ConA-med iated effects on COX-2 induction and MTI-MMP activat ion (F ig. l B). 
Following this, a ti me-course assay was performed with various concentrations of ConA. 
A loss in LRP- 1 expression occured within 30 minutes of treatment with ConA (Fig. l C, 
upper panel), and LRP-1 expression was complete ly abo li shed from lysates by 12 hours 
(F ig. l C, lower panel). Havi ng establ ished that the LRP- 1 expression declined in cell 
lysates, we questioned whether a mature 600-kDa LRP-1 sti ll trafficked and 
compartmenta li zed at the cell s urface. We performed immunophenotyping by flow 
cytometry to assess the rate at which LRP-1 was being internalized from and recyc led to 
the cell surface. U87 cell s were incubated for the indicated times with ConA and non-
penneabilized cell s immunomarked as described in the Methods section . Following 15 
minutes of ConA treatment, ce l! surface LRP-1 had decreased to 25% of that seen with 
the control treatment, and to 10% of contro l at 2 hours of treatment (F ig. l D, c losed 
circ les). LRP-1 gene expression, as assessed by qRT-PCR, was unaltered (Fig.l D, open 
circ les). Altogether, the combined data leads us to hypothes ize that mis-trafficking of 
LRP-1 to the cell surface poss ibly leads toits compartmenta li zed degradation . 
LRP-1 decrease is independent of MT1-MMP catalytic activity but corre/ales with 
ConA-mediated MT1-MMP proteolytic processing. To explore the link between ConA 
and LRP-1 , we next exam ined whether MTI -MMP wa involved in mediating the 
degradation of LRP-1 in ConA-activated U87 cell s. ConA is classica ll y used to trigger 
MTI-MMP-mediated activation of proMMP-2, wh ich is furt her retlected through MTI-
MMP proteo lytic activation. 3 1' 32 The broad acting MMP catalytic inhibitor llomastat was 
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thus used and validated through the inhibition of ConA -mediated proMMP-2 activat ion. 
Neither proMMP-2 activat ion nor gene ration of the proteolytically processed MTI-MMP 
43-kDa spec ies were observed in Jlomastat-treated ce lls (F ig.2A). T hi s effect was 
emulated by the efficient si lenc ing of MTI-MMP using RNA interference (Fig.2B), 
followed by treatment with ConA (F ig.2C). Furthermore, we tested whether Furin -
mediated LRP-1 maturation to the cell surface was involved . We found that inhibition of 
the proprotein convertase Furin, which is implicated in the maturation of LRP-1 into its 
85-kDa and 515-kDa subunits, did not prevent the decrease in the 85-kDa LRP-1 subunit 
expression, though partially inhibiting MT1-MMP proteolytic processing into its 43 -kDa 
species (F ig.2A). Th is observation potentially suggests that, upon cytoskeleton 
di sruption, a pool of intrace llular LRP-1 protein trafficking is rather directed towards 
degradation than recycled to the ce ll surface. 
LRP-1 loss is mediated by both the ubiquitin-dependent proteasome 5ystem and by 
lysosomes in ConA-activated U87 cel/s. As LRP- 1 has been reported to be degraded by 
the ubiqui tin-dependent proteasome system (UPS) and within lysosomes/ 7 we next 
examined whether either of these systems was active in ConA-activated U87 ce ll s. As 
almost complete disappearance of LRP-1 from ce ll lysates was observed withi n 6 hours 
of treatment, we chose to treat U87 ce ll s for this duration with var ious doses of UPS 
inhibitors, MG 132 or Lactacystin , in the presence or absence of ConA. Inhibition of the 
UPS was confirmed by immunodetection of ubiquitin, and a s ignificant rescue of LRP-1 
was observed (F ig.3A). Treatment w ith epigallocatechin 3-gall ate (EGCG), a green tea 
catechin known to inhibit the UPS,38 was unable to rescue the ConA -mediated LRP- 1 
decrease (Fig.3B). To assess whether lysosomal degradation was involved, we treated 
covers lip-seeded U87 cell s with ConA (30 f.Lg/ml) for 0, 2 and 6 hours, after which we 
labelled both lysosomes and LRP-1 in order to evaluate whether these were colocali zed. 
We found that, within 2 hours oftreatment, s ign ificant co localization between LRP -1 and 
lysosomes occurred, suggesting that the Joss of LRP-1 is performed within thi s 
compartment (Fig.3C). 
LRP-1 decreases in ConA-activated U87 cells is independent from ConA-mediated 
cel/ signalling. Having ru led out MT 1-MMP as a mediator of the observed ConA effects 
(Fig.2), we next tested whether ConA receptors TLR-2 and TLR-6 were involved. 
Blocking TLR-2 in vivo was shown to attenuate experimenta l hepatitis induced by ConA 
in mice.39 In parallel , TLR-6 gene silencing was found to abrogate ConA-induced CSF-2 
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and CSF-3 transcriptional regu lation.40 RN A interference a ll owed us to silence the 
expression of TLR-2 and TLR-6 which was fo llowed by a 6 hour treatment with ConA, 
this did not abrogate the ConA-i nduced LRP- 1 degradation (Fig.4A). We next inhibited 
severa! intracellular signalling pathways which could play a ro le in ConA signalling. 
However, despite sorne modul ation observed in LRP-1 immunodetections, it appeared 
that thi s rapid regulation and almost compl ete loss in LRP-1 was independent from the 
aforementioned mechanisms (F ig.48). 
Altered LRP-1 trafficking is triggered upon ConA-mediated alterations in actin 
cytoske/eton integrity. Having been unable to identify receptor-mediated signalling 
pathway linking ConA to the internali zation and degradation of LRP- 1, we explored 
ConA ' s abi lity to rather direct! y disrupt the cytoskeleton as a cause of the observed 
effects. ln order to compare ConA to other cytoskeleton-disrupting agents, U87 cells were 
treated with Cytochalas in-D (CytoD), an inhibitor of actin polymerization, and 
Nocodazole, an inhibitor of mi crotubule polymerization. We found that CytoD, in 
contrast to Nocodazole, emulated the effects caused by ConA in cel! lysates (F ig.5A). 
The internali zation of LRP-1 from the ce l! surface, as measured by flow cytometry, was 
agai n also emulated by CytoD but not by Nocodazole (F ig.5B). An immunofluorescent 
assay ofCytoD- and Nocodazole-treated U87 cells fai led to show colocali zation between 
LRP- 1 and lysosomes, although a decrease in LRP-1 fluorescence was observed by 
microscopy (Fig.5C) when ce ll s were treated with CytoD, but not with Nocodazole 
(Fig.S D). This suggests that, although common actin cytoskeleton perturbations are 
involved between the CytoD and ConA actions, differentia i compartmentation processes 
regulate ConA -mediated LRP-1 decreased express ion. Furthermore, one can also 
hypothes ize that LRP-1 incapacity to recycle back to the cel! surface triggers its 
intracellular proteolytic degradation. 
Reduced uptake of LRP-1 ligands resu/ts from LRP-1 loss from the cel/ surface. 
Having established a rapid loss of LRP-1 from the cel! surface , we next questioned 
whether thi s wou ld lead to any ligand-mediated internalization functional impairment. 
Thus, we carried out cellular uptake assays with physiological and synthetic LRP-1 
ligands in ConA-activated ce ll s. Followi ng 5 minutes of incubation with ConA, the 
cellu lar uptakes of both Alexa488-Angiopep-2 and Alexa488-a2-Macroglobulin decreased 
by ~60% (F ig.6A). To assess whether the observed degradation of cel! surface LRP- 1 
corre lated with the increas ing concentrations of ConA, we carried out an uptake assay 
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with Alexa488-Angiopep-2 foll owing 2 hours of ConA treatment (Fig.68 ). We observed a 
significant decrease in uptake by up to ~60% when treated with 30 j..Lg/ml ConA. To 
further support our findings, we treated U87 cells with varying concentrations of ConA 
fo r 2 hours, after which we incubated the cell s with Alexa488-Angiopep-2 and label led cell 
surface LRP-1 (F ig.6C). Quantification of these markers showed that the uptake of 
Alexa488-Angiopep-2 correlated directl y with LRP-1 ce ll swface expression, whereas 
high cell surface LRP-1 status resulted in high Angiopep-2 internalization (Fig.6 D). 
3.5 Discussion 
ln the current study, we questioned whether cytoskeleton remodeling, as it 
dynamica ll y occurs in invading cells, altered endocytic processes such as those that 
regulate LRP-1 recycling and ce ll surface ava il ability. We found that LRP-1 rapidly 
exited the ce ll surface of ConA-acti vated U87 glioblastoma ce ll s, a phenomenon that was 
unrelated to MT 1-MMP's catalyt ic activity. However, LRP-1 decreases correlated with 
ConA-induced MT I-MMP in tracellular proteolytic acti vation and with induction of the 
inflammation biomarker COX-2 expression. Consequently, decrease in ce ll surface LRP-
1 resulted in diminished binding to its phys iologica l 2-Macroglobulin or synthetic 
Angiopep-2 ligands. Our study implies that cytoskeleton integrity is required for LRP-1 
expression and recycling to the plasma membrane, and strengthens the pivotai 
requi rement of cell surface LRP-1 functions in the vectori zed transport of therapeutic 
Angiopep bi oconjugates into brain cancer ce ll s. 
Although the intrace llular compartments involved 111 endocytic recycling processes 
remain to be well-defined, LRP-1 ' s tethering to the actin cytoskeleton and foca l adhesion 
sites is an aspect of our study which confirms its abso lute requirement for activated 2-
Macroglobulin or Angiopep-2 internalization processes to efficiently occur. Further, we 
demonstrate that LRP-1 ' s expression and function can be sign ificantly regul ated upon 
ConA-mediated cytoskeleton reorgani zation which mimics the migrating/invading ce ll 
phenotype. 11'4 1 As a consequence, the mis-traffi cking of endosomal LRP-1 proteins may 
indeed affect cell mi grati on, a process that is essential fo r development, ti ssue 
remodeling, and wound healing, as we il as LRP-1 ligand recycling functions altered in 
many abnormal pathological states.42'43 To migrate directionall y, cells indeed require to 
coord inate temporal and spatial cytoskeleton rearrangements through acti n 
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polymerization and foca l adhesion turnover in order to generate the forces required for 
directional movement and cel! surface protein avai lab ility. 44 Among the processes which 
could regulate LRP-1 ce l! surface avai lab ility, the recycling endosome is an organe ll e in 
the endocytic pathway where plasma membrane proteins are internalized by endocytos is 
and processed back to the ce ll surface for reuse. This a llows the ce ll to maintain 
constituents of the plasma membrane on ce ll su rfaces. 45 Evidence using Brefeldin-A, a 
vesicu lar trafftcking inhibitor that trapped MT1-MMP within the ce ll , demonstrated 
simi lar induction of endoplasmic reticulum (ER) stress than ConA.31 White Nocodazole 
was ineffective, CytoD, a patent inhibitor of actin polymerization, reduced LRP-1 
expression to a leve! simi lar to that seen with ConA. Possible non-specifie effects of 
CytoD, which may alter various other processes within the ce ll , must here be 
acknowledged. The use of Latrunculin B, a specifie inhibitor of cytoskeleton 
polymerization,46 may ultimately help in demonstrating LRP 1 degradation is indeed 
mediated by cytoskeletal disruption. Thi s is now mentioned in the Discussion sect ion of 
the revised manuscript. lnterestingly, si lencing of MTI-MMP prevented ConA from 
inducing both ER stress and COX-2 express ion, but was unable to prevent ConA-
mediated LRP- 1 attenuation (this study). Inhibition of furin-depe ndent MTI-MMP 
proteolytic processing by ConA was also ineffective at reversing the LRP-1 decrease in 
our hands, although a potential mature ~600 kDa LRP-1 unprocessed form may have 
been expected to be observed and required to be further investigated. 
The use pharmacological endocytosis and lysosomes inhibitors, as we il as proteasome 
inhibitors (as performed in Fig.3 with the use of MG 132 and Lactacystin), may in the 
future studies help in our data interpretation regarding LRP-1 recycling processes. Of the 
recent molecular players demonstrated to link vesicular trafftcking processes to cancer 
cell migration and invasiveness, the functions of the Rab fami ly of small GTPases in 
regulating vesicu lar transport has raised intriguing mechanistic insights.47 For instance, a 
Rab 1 !-dependent recycling pathway was repo1ted to regulate a2-Macroglobul in!LRP 1-
induced cellular migration of Müller glial cells by a mechanism that involved MTI-MMP 
intracellular trafficking to the plasma membrane. 48 Furthermore, a specifie subset of 
RabGTPases was found to contro l ce l! surface exposure ofMTI-MMP, ECM degradation 
and three-dimensional invasion of macrophages.49 Whether any of these Rab proteins are 
also involved in LRP-1 internalization is unknown. Such evidence, however, points to the 
existence of possible crossta lk between these processes. LRP-1 internalization and 
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recycl ing back at the cel! surface from early endosomes is a rapid (0.5 minutes) and high 
capacitive process,50 and it becomes reasonabl e to hypothesize that disruption of these 
networks may rather lead to compartmentalized degradation of LRP- 1 poss ibly by the 
UPS and via lysosome. lnterestingly, EGCG, a green tea catechin known to inhibit 
severa! ConA- and MT I-MMP-mediated processes,22.4°.51 and which also inhi bited some 
Ubiquitin-Proteasome properties,52 had no effect on the ConA-mediated LR.P-1 decrease. 
Given that neither TLR.-2 sil encing, TLR.-6 silencing nor inhibition of multiple signalling 
pa th ways resul ted in any reversai of LRP-1 decrease, we con cl ude th at LRP-1 decreases 
are unrelated to any ce l! surface ConA-induced signa ling pathway but rather caused 
through Co nA 's capacity to alter cytoskeleton integrity and, hence, traffi cking/recycl ing 
processes. 
Finally, ConA is a pl ant lectin that has also been used for its properti es in inducing a 
pl ethora of cellul ar events including ce ll proliferation and cel! death/survi val, as we il as 
molecular biomarkers expression such as cytokines secretion,40•53 nitric oxide synthesis,54 
intlammatory COX-2 express ion,30.32•36 autophagy BNIP-3 expression,33.55 and acti vati on 
and transcription of MT I-MMP.56' 57 ConA has thus begun to be explored as a potential 
therapeutic entity due to its ability to induce both autophagy and apoptosis in human 
cancer ce l! models including hepatoma, glioblastoma, melanoma, and breast cancer 
cell s.54.58-60 lt is thus considered as a potential antineoplastic in preclinical or clinical trials 
for cancer therapeutics. lnterestingly, it has been inferred that LRP- 1 could mediate tox in-
induced autophagy and apoptosis in a human gastri c epithelial cell model. 61 Due to 
ConA ' s potential as a therapeutic avenue, it will be usefu l to understand how it 
co llecti ve ly affects MTI-MMP and LR.P-1 regulation in tumour ce ll s. 
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3.7 Figure Legends 
Fig.! : ConA triggers a rapid decrease of LRP-1 expression in U87 cells. (A) Serum-
starved U87 cells were treated for 24 hours with vari ous concentrations of 
Concanavalin-A (ConA). Cell lysates were iso lated and processed for the 
immunodetecti on of COX-2, MTJ-MMP, LRP-1 (85-kDa subunit), and GAPDH . 
Conditioned media were harvested in order to assess proMMP-2 activation using 
gelatin zymography (bottom pane l). (8) Representative densitometry analys is of 
LRP-1 to COX-2 express ion (left panel) and LRP- 1 to MT I-MMP proteolyti c 
process ing (43 -kDa form 1 55-kDa form ratio, right panel). (C) Serum-starved 
U87 ce ll s were treated with various concentrations of ConA. Ce l! lysates were 
isolated, and immunodetection of LRP- 1 for the indicated times performed. (0 ) 
Representati ve cell surface immunophenotyping of LRP-1, as measured by fl ow 
cytometry (c losed circles), and assessment of LRP-1 gene express ion as measured 
by qRT-PCR (open circles) are presented relati ve to time oftreatment with ConA 
30 g/ml. 
Fig.2: ConA-induced LRP-1 degradation is independent of MT1-MMP catalytic or 
proteolytic maturation. (A) Serum-starved U87 ce ll s were treated (or not) fo r 24 
hours with ConA (30 11g/ml ) or with llomastat (25 11M) ± Furin inhibitor Il (50 
11M) (as a co-treatment, or as a 24 hours pre-treatment). Conditioned media were 
harvested to assess proMMP-2 acti vation by gelatin zymography (bottom 
images) . (B) U87 ce ll s were transiently-transfected with siScrambled (siScr) or 
siMTl-MMP and transfection effici enty confirmed by qRT-PCR, then (C) 
fo llowed by treatment fo r 24 hours with or without ConA (30 11g/ml ). Foll owing 
treatments, cell lysates were isolated for immunodetection of MT l-MMP, LRP-1 
(85-kDa subunit), or GAPDH. Condi tioned med ia were harvested to assess 
proMMP-2 acti vation by gela tin zymography (bottom of panel). 
Fig.3: LRP-1 degradation in ConA-activated U87 cells is mediated both by 
lysosomes and by the UPS. U87 cells were treated for 6 hours, in the presence or 
absence of ConA (30 !lg/ml) with (A) the UPS inhi bitors MG 132 (Left panels) or 
Lactacystin (Right panels) or (8) EGCG (25 11M). ln a li conditions, ce l! lysates 
were iso lated for immunodetection of MT l-MMP, LRP-1 (85-kDa subunit), 
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GA PDH and Ubiquitin (panel A only). (C) U87 cell s were seeded onto coverslips 
where they were treated (or not) with ConA (30 ~tg/ml) fo r 2 and 6 hours. Cell s 
were then incubated with Lysotracker (red), fixed , and stai ned for LRP-1 (green). 
Images were acquired using a Nikon Eclipse Ti confoca l microscope and using 
N IS Elements software. Deconvolution and coloca li zation analys is was carried 
out with AutoQuant X software. Coloca li zation analysis revea led Pearson 's 
Correlation Coefficients (t=Oh, 0.59; t=2h, 0.99; t=6h, 0.99) and 2D histogram 
plots of coloca li zation inset (green, y-axis (LRP-1 ); red, x-axis (Lysotracker)). 
Fig.4: LRP-1 degradation in ConA-activated U87 cells does not require cell 
surface-mediated cell signalling. (A) U87 cell s were transiently-transfected with 
10 nM of either siScr, siTLR-2 or siTLR-6, and transfection efficacy assessed by 
qRT-PCR. (8) Following ConA treatment, a li cel! lysates were used for 
immunodetection of LRP-1 (85-kDa subun it) and GAPDH. (C) U87 cells were 
treated for 6 hours in the presence or absence ofConA (30 ~g/ml) in combination 
with the JAK/STAT inhibitor Tofacitanib (CB, 30 ~M), the MAPK inhibitor 
SB203580 (SB, 10 ~M), the Src inhibitor PP2 (PP2, 10 ~M), the MEK inhibitor 
UO 126 (UO, 20 ~M), or the MAPK inhibitor Acety l-11 -keto-beta-boswellic acid 
(AKBA, 20 ~M). 
Fig.5: Disruption of the actin cytoskeleton is responsible for LRP-1 internalization 
and degradation. (A) U87 cell s were treated for 6 hours with ConA (30 ~g/ml) , 
CytoD ( 1 and 0.1 ~) or Nocodazole (300 and 30 nM). Cel! lysates were then 
isolated for immunodetection of LRP- 1 (85-kDa subun it), MT 1-MMP and 
GAPDH. (8) U87 ce ll s were treated for 2 hours with ConA (30 ~g/m l ) , CytoD ( 1 
~tM) or Nocodazole (300 nM). Cell s were then harvested for immunophenotyping 
of ce l! su rface mature 600-kDa LRP-1 by flow cytometry. (C) U87 ce ll s were 
seeded onto coversl i ps and treated with CytoD ( 1 and 0.1 ~M) or Nocodazole 
(300 and 30nM) for 6 hours. Ce ll s were then incubated with Lysotracker (red), 
fixed , and stained for LRP-1 (green), or for the nucleus with DAPI (blue). Images 
were acquired with a Nikon Eclipse Ti confoca l microscope and using NIS 
Elements software, deconvolution and colocalization ana lysis was carried out 
with AutoQuant X software. (D) Mean ce l! surface LRP- 1-assoc iated 
fluorescence was measured using lmajeJ software and divided by number of 
nuclei (arb. units). 
Fig.6: ConA-induced LRP-1 internalisation and degradation leads to a reduced 
uptake of LRP-1 ligands. U87 ce lis were treated with ConA (30 ~g/ml) for up to 
120 minutes, followed by incubation with Alexa488-labelled LRP-1 ligands (A) 
a2-Macroglobulin or (8) Angiopep-2 (left panel). Uptake of 1 igands was 
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measured by flow cytometry. (B) U87 cells were treated with various 
concentrations of ConA (0-30 ~J.g/ml) for 2 hours, fo llowing which Angiopep-2 
uptake was assessed. (C) U87 cell s were plated on coverslips and treated with 
various concentrations of ConA for 2 hours, then subsequently incubated with 
A lexa488-label led Angiopep-2 (Top panels, green). Fixed cell s were stained for 
LRP- 1 (bottom panels, red) and images were acquired with a Nikon Eclipse T i 
confoca l microscope using NIS Elements software. Images shown are from a 
representative experiment. (D) Relative Angiopep-2 interna li sat ion as a function 
of LRP-1 cel l surface expression; Li near regression (R2 = 0.92). 
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Chapter III 
4 Conclusions 
Our finding that ConA-mediated cytoskeleton disruption results in the rapid 
internalization and complete degradation LRP-1 will contribute to both the study of LRP-
1, and that of the malignant phenotype in GBMs. Furthermore, one can imagine that these 
new data may give context to future studies involving modulation of LRP-1 and/or the 
cytoskeleton. 
Given that our laboratory has reported that MTI-MMP is able, when 
overexpressed in U87 cells, to reduce cell surface LRP-1 expression, it was somewhat 
unexpected to find that the phenomena of ConA-induced-LRP- 1 processing was 
independent of MTI-MMP. lt would have been expected to see some ki nd of reduction in 
the LRP-1 degradation found when inhibiting MT1-MMP catalytic function. However, as 
we did not, the processing of LRP-1 in MT1-MMP overexpressing ce lls may be much 
less significant than to that we see in our current study. Furthermore, the reduction in 
expression of LRP-1 in MT1-MMP over-expressing cells, is via a direct interaction of 
proteolytic cleavage. Due to the relative speed at which we observe LRP-1 being 
trafficked away from the ce ll surface (within minutes) and degraded within the cell (<30 
minutes; Figure 1 - Chapter 2), any induction of MTI-MMP-mediated proteolysis of 
LRP-1 , that cou ld have been expected in our ConA-activated U87s, would take longer to 
show an effect than for LRP-1 to exit the cell surface (as observed in our study), and thus 
unava ilab le for MT1-MMP cleavage. 
The finding that LRP-1 exited the cell surface as a result of actin-cytoskeleton 
disruption further contributes to body of evidence describing LRP-1 's role in cytoskeleton 
processes. (Boucher et al. , 2008; Li llis et al. , 2005) This is especia lly relevant due to the 
nature of migration and invas ion, both in physiologica1 and pathological contexts, where 
the cytoskeleton is involved in the mechanical and physical changes that provide a 
movement component to migration and invasion (A lbert, B. , 20 1 0). Furthermore, the 
cytoskeleton is involved in the mediation of attachment and anchoring of the ce li to either 
the basement membrane and/or cells (Fischer & Fowler, 2015). Given the important role 
LRP-1 plays in clearance of extracellular proteases (Etique, Yerzeaux, Dedieu, & 
Emonard, 20 13), it would seem logical for this fun ct ion of LRP-1 to be repressed in the 
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migratory front of cell s. However, this wou ld be a naïve and pre-emptive conclusion to 
draw from the data we present. This phenomena of such s ignificant LRP-1 regulation on, 
what should be considered extreme, modulation of the actin cytoskeleton, merits further 
study. lt would be extremely pertinent to determine whether the internalization and 
degradation of LRP-1 is as a result of disruption to the actin cytoskeleton, without doubt. 
Furthermore, to develop on the hypothesis that this ConA-mediated actin cytoskeleton 
di sruption mimics the migratory 1 invasive phenotype, it would be revealing to quantify 
and locali se LRP-1 during the migratory process. Additionally, by visualising the 
cytoskeleton during this process it may be possible to correlate both events to support the 
claim that LRP-1 is exiting the cel! surface as a result in the dynamic changes that occur 
during cellu lar migration. Given that our study was carried out in an aggressive glioma 
cel lline, whether th is process - ofLRP-1 internalization - is a characteristic ofa highly 
malignant phenotype would also be interesting to probe (since interest in LRP-1 status in 
severa! different pathologies is being explored as a possible indicator, negative and 
positive). 
1 nterestingly, it has recent! y been demonstrated that LRP-1 can contribute to the 
recruitment of monocyte to the tumour compartment, attributed to its abi lity to promote 
vascu larisation of the tumour (Staudt et al., 20 13). As we have demonstrated th at Co nA is 
able to rapidly remove LRP-1 from the ce l! surface, thi s provides more support for ConA 
to be further stud ied as a potential therapeutic entity given the growing implications of 
LRP-1 in pathological mechanisms. Despite being unable to give certainty to the link 
between ConA and CytoD to LRP- 1 degradation, this is strong evidence for caution and 
diligence to be used when disrupting the actin-cytoskeleton alongside LRP-1 targeting 
drug delivery methods, such as the Angiopep peptides. Figure 6 showing significant 
functional impairment of LRP- 1-mediated internalization of ligands at ConA (3 1-lg/ml ) 
(F ig ure 6B), as weil as functional impairment within 5 minutes of ConA exposure (Figure 
6A). Functional impairment was maximally around 40-60% of control, most likely due to 
the nature of both Angiopep-2 and a.2-Macroglobu lin (neither being purely LRP-1 
specifie ligands). Figure 6C showed clearly a correlation between LRP-1 cell surface 
expression and the internalization of Angiopep-2. 
Due to the dynamic role the actin cytoskeleton can play in cancers, interest has 
been placed in developing agents that are anti-actin. However, there are no current anti-
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actin agents used in chemotherapy due to thei r indi scrim inate inhibition of the fil aments 
of the muscle sarcomere. Recent! y, Stehn et al, (Stehn et al. , 20 13) demonstrated that it 
was poss ible to "target specifie actin fil ament populations fundamental to tumour cel! 
viability based on their tropomyosin isoform composition. This improvement in 
specificity prov ides a pathway to the development of a novel class of anti-actin 
compounds for the potential treatment of a wide variety of cancers." Importantly, with 
increased specificity, cardiac muscle was unaffected by the inhibition. As the metastati c 
state is one of the fundamental transformations that di fferentiate benign from potenti ally 
fatal tumours, being able to inhibit this specifi e process may weil be signifi cant. Given 
the poss ible impl ica ti ons of ac tin cytoskeleton disruption on LR.P-1 , our study provides 
the initial ev idence that warrants further experimental inquiry into the effects of actin 
cytoskeleton-targeting-therapy on LR.P-1 status. Therefore, a pertinent next step in our 
research would be to explore these potenti al novel classes of chemotherapeuti c agents on 
LR.P-1 status within both cancerous and physiological ce l! models. 
An emerging ro le for microtubul es in tumour ce l! metastasis is being unrave lled 
and there is increas ing interest in the crosstalk between key microtubul e interacting 
proteins and the actin cytoskeleton, which may provide novel treatment avenues for 
metastat ic di sease. (Fife et al. , 20 14) Perhaps another useful avenue to explore 
subsequently to our results - having confirmed that the LR.P-1 depleti on seen in our 
research is certainly due to actin cytoskeleton disruption - would be to identify the 
regul atory proteins involved in thi s regulation of LR.P-1 . As mentioned bri efl y in the 
results section (5.5 Discussion, Chapter 2), there is a RabGTPase family of proteins that 
pl ay an integral role in regulating MT I-MMP traffi cking in primary human macrophages. 
(Wiesner et al. , 20 13) These proteins, specifically Rab5a, Rab8a and Rab 14, in media ting 
the tethering of ves icles to target organelles, give a means of control in the regulation of 
endocytotic and exocytotic processes of MTI-MMP. lt is also suggested that Rab7a plays 
a role in mediating the deli very of ves icle to lysosomes for degradation. An attractive 
next step in developing our understanding of LRP-1 internalisati on and degradation 
during ConA-meditated actin cytoskeleton disrupti on, would be to asses whether these 
sets of RabGTPases, or whether others - given that there are over 70 known mammalian 
Rab GTPases (Hutagalung & Novick, 2011 )- play a simil ar role in U87 cell s. An initial 
gene silencing screening of Rabs 5a, 8a, and 14, as we il as 7a, would present as an 
attractive fi rst step in exploring whether similar mechanisms occur in our mode!. The 
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ident ification of a spec ifie mechani sm linking the internali zation and degradation of LRP-
1 would be an interesting addition to the understanding of LRP- 1 regulation and 
functions. Perhaps the regulation of LRP-1 is mediated by its own set of Rab GTPases, or 
the di sruption of the actin cytoskeleton results in perturbations of LRP- l endocyti c and 
exocytic processes, via Rab proteins. Given the re lationship LRP- 1 and MT 1-MMP share, 
it would be attractive to assume that the same fa mily of proteins regulate their process ing. 
However, thi s would be short sighted given the roles played by other small G prote in 
fa milies: both Arf or Rho have an integral role, alongs ide the Rab prote ins, during 
endocytos is and exocytosis, and are also an avenue worth exploring to find link between 
LRP-1 regulation and cytoskeleton di sruption. (Doherty & McMahon, 2009) Given that 
Rho small G prote ins are invo lved in cytoskeleton regulation, it would be interesting to 
see whether thi s is as a result of, or a cause of the phenomena we see. (Doherty & 
McMahon, 2008) 
As has been di scussed, LRP-1 functions are still not fully characteri zed, and it 
can be presumed that much of the paradoxical information we have on L RP- 1 function 
are due to the lack of a fully integrated understanding. A good example of thi s is, despite 
LRP- 1 ' s ro le in c learing extra-cellular proteases from the extra-ce llular compartment, 
LRP-1 has been shown to be invol ved in the induction of both MMP-2 and -9, a lbeit in 
endometrial explants and not cancer cel! mode ls. (Se lvais et a l. , 2009) Thus, phenomena 
such as thi s may weil become more clear following a broader understanding of the 
di fferent capacities LRP- 1 has: it is able to induce and transmit severa! intrace llular 
processes, that may or may not, be linked to its functi ons in the extrace llular 
compartment. Given that LRP-1 status has been assoc iated with both protecti ve and 
de leteri ous effects in patho logies, it w ill be interesting to see how these superfi cially 
nonsensical phenomena are explained. 
To conclude, due to LRP- 1 ' s broad implications, both pos iti ve and negati ve, in 
signi fi cant pathologies such as neurodegeneration, cardiovascular di sease and many 
fo nns of cancer, our contribution to the understanding of its regu lation will be we lcomed. 
Furthermore, our work provides data to suppor1 the clai m that ConA, as a potential 
therapeuti c entity, merits continued explorat ion. 
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